Hepatic Clearance of Tissue-Type Plasminogen Activator in Rats

Summary

The clearance of tissue-type plasminogen activator (t-PA) was studied, in rats, by use of a functional assay for t-PA. Half-lives in the circulation were about one minute both for human (melanoma cell-derived) t-PA and for the rat’s own t-PA. The clearance of t-PA required an intact liver blood flow. In isolated liver perfusion experiments the hepatic extraction of t-PA did not require any plasma proteins, including fast-acting t-PA inhibitor. Competition experiments, using monosaccharides, suggested that known hepatic glycoprotein receptors were not involved in hepatic t-PA extraction.

Keywords

Rat - Tissue-type plasminogen activator - Clearance - Liver - Carbohydrate - Tunicamycin

• References

• 1 Chmielewska J, Rânby M, Wiman S. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
• 2 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 3 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
• 4 Wiman B, Chmielewska J, Rânby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3647
• 5 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111-118
• 6 Rijken DC, Wijngaards G, Welbergen J. Relationship between uterine tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
• 7 Kristensen P, Larssen LI, Nielsen LS, Grøndahl-Hansen J, Andreasen PA, Danø K. Human endothelial cells contain one type of plasminogen activator. FEBS Letters 1984; 168: 33-37
• 8 Markwardt G. Gefäßwand und Fibrinolyse. Arzneimittelforschung/ Drug Research 1983; 33: 1370-1374
• 9 Nolf P. Les modifications de la coagulation du sang chez le chien après l’extirpation du foie. Arch Int Physiol 1905; 3: 01-43
• 10 Wasantapruek S, Von Kaulla KN. A serial micro-fibrinolysis test and its use in rats with liver bypass. Thrombos Diathes Haemorrh 1966; 15: 284-293
• 11 Von Kaulla KN, Von Kaulla E, Wasantapruek S. Rapid increase of fibrinolytic activity in pig and rat after exclusion of the liver from the circulation and its control by various organs. Acta Hepato-Gastroen-terol 1979; 26: 4-8
• 12 Emeis JJ. Perfused rat hindlegs. A model to study plasminogen activator release. Thromb Res 1983; 30: 195-203
• 13 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
• 14 Nilsson S, Matsson Ch, Häggroth L. The elimination and the thrombolytic effect of the plasminogen activator in normal and hepatectomized rabbits. Thromb Haemostas 1983; 50: 296 (Abstr.)
• 15 Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 1984; 33: 49-53
• 16 Emeis JJ. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemostas 1983; 50: 295 (Abstr)
• 17 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 18 Kluft C, Van Wezel AL, Van der Velden CAM, Emeis JJ, Verheijen JH, Wijngaards G. Large-scale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells. In: Advances in biotechnological processes Mizrahi A, Van Wezel AL. (Eds) A R Liss Inc; New York: 1983. 2 097-110
• 19 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 20 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
• 21 Gallimore MJ. Effect of diluents on blood clot lysis. J Clin Path 1967; 20: 234-238
• 22 Emeis JJ. Platelets and the dilute blood clot lysis. In: Haemostasis and Thrombosis Neri Serneri GG, Prentice CRM. (Eds) Academic Press; New York: 1979: 769-772
• 23 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
• 24 Emeis JJ, Kluft C. PAF-acether-induced release of tissue-type plasminogen activator from vessel walls. Blood 1985; 66: 86-91
• 25 Achord DT, Brot FE, Bell CE, Sly WS. Human β-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978; 15: 269-278
• 26 Tkacz JS, Lampen JO. Tunicamycin inhibition of polyisoprenyl N-acetyl-glucosaminyl pyrophosphate formation in calf liver microsomes. Biochem Biophys Res Comm 1975; 65: 248-257
• 27 Takatsuki A, Kohno K, Tamura G. Inhibition of biosynthesis of polyisoprenol sugars in chick embryo microsomes by tunicamycin. Agr Biol Chem 1975; 39: 2089-2091
• 28 Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol 1974; 41: 099-128
• 29 Steer CJ, Clarenburg R. Unique distribution of glycoprotein receptors on parenchymal and sinusoidal cells of rat liver. J Biol Chem 1979; 254: 4457-4461
• 30 Prieels J-P, Pizzo SV, Glasgow LR, Paulson JC, Hill RL. Hepatic receptor that specifically binds oligosaccharides containing fucosyl α1 → 3 N-acetylglucosamine linkages. Proc Natl Acad Sci USA 1978; 75: 2215-2219
• 31 Toth CA, Thomas P, Broitwan SA, Zamcheck N. A new Kupffer cell receptor mediating plasma clearance of carcinoembryonic antigen by the rat. Biochem J 1982; 204: 377-381
• 32 Imber MJ, Pizzo SV. Clearance and binding of native and defucosylated lactoferrin. Biochem J 1983; 212: 249-257
• 33 Fuchs HE, Shifman MA, Michalopoulos G, Pizzo SV. Hepatocyte receptors for antithrombin III-proteinase complexes. J Cell Biochem 1984; 24: 197-206
• 34 Robinson JH. Enzyme derivatives and their use in the treatment of thrombosis. Int Patent Application PCT/GB 83/00273 1983
• 35 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-6808
• 36 Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 099-110
• 37 Fuchs HE, Berger H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-544
• 38 Rijken DC, Emeis JJ, Gerwig GJ. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells. Thromb Haemostas 1985 (in press)